💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

UPDATE 1-Roche to ease Tamiflu access in developing countries

Published 07/01/2009, 01:32 AM
Updated 07/01/2009, 01:57 AM

* Roche to produce, store Tamiflu at reduced price

* To ship stockpile once influenza pandemic declared

(adds details on programme, background)

ZURICH, July 1 (Reuters) - Swiss drugmaker Roche has launched a programme to ease access to its antiviral drug Tamiflu for developing countries, the group said on Wednesday.

The programme should ensure that Tamiflu (oseltamivir) is available to many developing nations if the World Health Organization (WHO) declares an influenza pandemic, or for the management of a novel influenza strain defined by the WHO as having significant and current pandemic potential, it said.

Under the programme, which will take effect immediately, Roche will produce and store Tamiflu pandemic stockpiles for specified developing countries at a significantly reduced price with the cost spread over a number of years, the group said.

Roche will then ship the stockpile to the governments of countries concerned when an influenza pandemic has been announced, or in the event of a public health emergency, upon request from the governments concerned, it said.

The countries can exercise their option to purchase the product at any time, Roche said. The WHO has declared a global pandemic is underway from the virus known as swine flu which has so far been treatable with Tamiflu. (Reporting by Sven Egenter; Editing by Hans Peters)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.